menu
    • menu
    [{"orgOrder":0,"company":"OncoZenge","sponsor":"Baltic Sea Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"OncoZenge","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"OncoZenge \/ Baltic Sea Foundation","highestDevelopmentStatusID":"8","companyTruncated":"OncoZenge \/ Baltic Sea Foundation"},{"orgOrder":0,"company":"OncoZenge","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OncoZenge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"OncoZenge \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"OncoZenge \/ University of California"}]

    Find Clinical Drug Pipeline Developments & Deals by OncoZenge

    Menu

    OncoZenge

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncoZenge

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoZenge

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : University of California

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            OncoZenge Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge

                            Details : The partnership focuses on a patient engagement study in managing oral mucositis pain, while exploring potential pathways toward a future IND application for BupiZenge.

                            Product Name : BupiZenge

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 17, 2025

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : University of California

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OncoZenge

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoZenge

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Baltic Sea Foundation

                            Deal Size : $8.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            OncoZenge Secures Approximately SEK 70 Million in Financing Ahead of spin-off and separate listing

                            Details : OncoZenge is developing the BUPI project under the BupiZenge ® brand , for the treatment of pain due to oral mucositis, a serious side effect of cancer treatment. BupiZenge ® has shown promising results in a phase 2 study. The capital will be used to f...

                            Product Name : BupiZenge

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 16, 2020

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Baltic Sea Foundation

                            Deal Size : $8.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth